STRATEC Biomedical Systems AG / Quarter Results/Preliminary Results
21.04.2009
Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC with substantial sales and earnings growth in first quarter of 2009
Birkenfeld, April 21, 2009
STRATEC Biomedical Systems AG (Frankfurt: SBS; Prime Standard) announces
the preliminary unaudited consolidated figures of the STRATEC Group for the
first quarter of the 2009 financial year as of March 31, 2009 pursuant to
IFRS (International Financial Reporting Standards) and in accordance with
Section 15 of the German Securities Trading Act (WpHG).<pre>
Key Figures (Euro 000s) 01.01.- 03.31.2009 01.01.- 03.31.2008 Change
Sales 16,727 13,208 + 26.6%
Gross performance 19,052 14,767 + 29.0%
EBITDA 3,311 2,691 + 23.0%
EBIT 2,724 2,110 + 29.1%
EBT 2,917 2,167 + 34.6%
Consolidated net income 2,111 1,661 + 27.1%
Earnings per share (Euro) 0.19 0.15 + 26.7%
EBIT margin (%) 16.3% 16.0%</pre>
Including temporary personnel, the STRATEC Group had a total of 289
employees as of March 31, 2009 (previous year: 264).
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
STRATEC Biomedical Systems AG increased its sales by 26.6% to Euro 16.7
million and its consolidated net income by 27.1% to Euro 2.1 million in the
first quarter of 2009. This growth was mainly driven by a further increase
in production and turnover figures.
The temporary reduction in turnover with one of our most important
customers is now easing, although the sales generated with this customer in
the first quarter of 2009 did not quite reach the level seen in the
equivalent period in the previous year. Due to this, as well as to the
different sales contributions made by individual production locations with
varying income tax rates across the Group, the Group's tax rate rose to
27.6% (Q1 2008: 23.3%, FY 2008: 34.7%).
The volume of down payments received (milestone payments made by customers
for STRATEC's development work) has risen by Euro 1.2 million compared with
December 31, 2008.
Although personnel expenses grew significantly between April 1, 2008 and
March 31, 2009 due to the hiring of new employees in the development
division (in preparation for forthcoming marketing launches) the Group
nevertheless increased its margins through economies of scale and further
expanding its consumables business.
Our long-term company growth is secured by numerous development and supply
agreements. In particular, the development status of existing development
projects, as well as the projects currently in the process of being
initiated, indicate positive business performance. On April 8, 2009, and in
conjunction with our audited 2008 results, we published financial guidance
for the full year 2009. Accordingly we continue to expect sales growth of
between 20% and 30% generating EBIT margins of between 18.5% and 19.5%.
In contrast to previous practice, STRATEC will in future refrain from
publishing preliminary quarterly figures and preliminary year-end figures
unless otherwise required by law. Regular reporting will hereafter be based
on the dates as published in our financial calendar.
The full interim report as of March 31, 2009 will be available for
downloading from our website from around 3 p.m. (CET) on May 14, 2009.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir@stratec-biomedical.de
DGAP 21.04.2009
---------------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STRATEC with substantial sales and earnings growth in first quarter of 2009
| Source: EQS Group AG